Cases & Deals

Pharnext completes €30.9 million IPO on Alternext market of Euronext in Paris

Clients Pharnext SAS

Jones Day represented Pharnext SAS, a biopharmaceutical company that develops new treatments targeting simultaneously several pathological mechanisms in neurological diseases, in connection with the €30.9 million (US$34.4 million) initial public offering on the Alternext market of Euronext in Paris.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.